1386 related articles for article (PubMed ID: 25800760)
1. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
2. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
Ahmed N; Brawley V; Hegde M; Bielamowicz K; Kalra M; Landi D; Robertson C; Gray TL; Diouf O; Wakefield A; Ghazi A; Gerken C; Yi Z; Ashoori A; Wu MF; Liu H; Rooney C; Dotti G; Gee A; Su J; Kew Y; Baskin D; Zhang YJ; New P; Grilley B; Stojakovic M; Hicks J; Powell SZ; Brenner MK; Heslop HE; Grossman R; Wels WS; Gottschalk S
JAMA Oncol; 2017 Aug; 3(8):1094-1101. PubMed ID: 28426845
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
Feng K; Guo Y; Dai H; Wang Y; Li X; Jia H; Han W
Sci China Life Sci; 2016 May; 59(5):468-79. PubMed ID: 26968708
[TBL] [Abstract][Full Text] [Related]
5. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
Ahmed N; Salsman VS; Yvon E; Louis CU; Perlaky L; Wels WS; Dishop MK; Kleinerman EE; Pule M; Rooney CM; Heslop HE; Gottschalk S
Mol Ther; 2009 Oct; 17(10):1779-87. PubMed ID: 19532139
[TBL] [Abstract][Full Text] [Related]
8. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
9. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
Vitanza NA; Johnson AJ; Wilson AL; Brown C; Yokoyama JK; Künkele A; Chang CA; Rawlings-Rhea S; Huang W; Seidel K; Albert CM; Pinto N; Gust J; Finn LS; Ojemann JG; Wright J; Orentas RJ; Baldwin M; Gardner RA; Jensen MC; Park JR
Nat Med; 2021 Sep; 27(9):1544-1552. PubMed ID: 34253928
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
11. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
Huang X; Park H; Greene J; Pao J; Mulvey E; Zhou SX; Albert CM; Moy F; Sachdev D; Yee D; Rader C; Hamby CV; Loeb DM; Cairo MS; Zhou X
PLoS One; 2015; 10(7):e0133152. PubMed ID: 26173023
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
[TBL] [Abstract][Full Text] [Related]
13. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
14. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
[TBL] [Abstract][Full Text] [Related]
15. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA
Zhang C; Wang Z; Yang Z; Wang M; Li S; Li Y; Zhang R; Xiong Z; Wei Z; Shen J; Luo Y; Zhang Q; Liu L; Qin H; Liu W; Wu F; Chen W; Pan F; Zhang X; Bie P; Liang H; Pecher G; Qian C
Mol Ther; 2017 May; 25(5):1248-1258. PubMed ID: 28366766
[TBL] [Abstract][Full Text] [Related]
16. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
17. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
18. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
19. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
[TBL] [Abstract][Full Text] [Related]
20. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
Wang Y; Zhang WY; Han QW; Liu Y; Dai HR; Guo YL; Bo J; Fan H; Zhang Y; Zhang YJ; Chen MX; Feng KC; Wang QS; Fu XB; Han WD
Clin Immunol; 2014 Dec; 155(2):160-75. PubMed ID: 25444722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
